GBIO Generation Bio

Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit

Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit

CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the virtual 2024 TD Cowen Genetic Medicines & RNA Summit on Friday, June 21st, 2024 at 1:50 p.m. ET.

A live webcast of the presentation will be available on the investor section of the company’s website at . A replay will be available there for 30 days following the event.

About Generation Bio

Generation Bio is innovating non-viral genetic medicines to provide durable and redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). With these platforms, Generation Bio aims to develop the next wave of non-viral genetic medicines to support its mission to extend the reach of genetic medicine to more people living with more diseases, around the world.

For more information, please visit .

Investors and Media Contact

Maren Killackey

Generation Bio



857-371-4638



EN
14/06/2024

Underlying

GBIOGeneration Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Generation Bio

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
02/09/26 February 9, 2026 1 EN
Wedbush Research
  • Wedbush Research
TSLA TESLA INC
GOOGL ALPHABET INC. CLASS A
AMZN AMAZON.COM INC.
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
GBIO GENERATION BIO
DASH DOORDASH
PAY PAYMENTUS HLDGS INC
TYRA TYRA BIOSCIENCES INC
CART MAPLEBEAR INC.
12/16/25 December 16, 2025 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
12/16/25 December 16, 2025 1 EN
 PRESS RELEASE
Free
GBIO GENERATION BIO

XOMA Royalty Enters into Agreement to Acquire Generation Bio

XOMA Royalty Enters into Agreement to Acquire Generation Bio - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna - - Generation Bio’s cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty’s portfolio - EMERYVILLE, Calif. and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has entered into an ag...

December 15, 2025 1 EN
 PRESS RELEASE
Free
GBIO GENERATION BIO

Generation Bio Announces Third Quarter 2025 Financial Results

Generation Bio Announces Third Quarter 2025 Financial Results CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: GBIO), a biotechnology company, today reported third quarter financial results. Third Quarter 2025 Financial Results Cash Position: Cash, cash equivalents, and marketable securities were $89.6 million as of September 30, 2025, compared to $185.2 million as of December 31, 2024. The company expects that its cash, cash equivalents, and marketable securities will fund its operating expenditures for the foreseeable future.R&D Expenses: Research and development (R&D) e...

November 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch